• Explore /
  • Poster
  • / HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.

HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.

Abstract Poster

Authors

Aleix Prat, Sr

Aleix Prat

Department of Medical Oncology, Hospital Clinic, Barcelona, Spain

Aleix Prat , Carmine De Angelis , Tomás Pascual , Carolina Gutierrez , Antonio Llombart-Cussac , Tao Wang , Javier Cortes , Brent Neil Rexer , Jamunarani Veeraraghavan , Andres Forero-Torres , Antonio C. Wolff , Serafin Morales , Ian E. Krop , Anne Clarisse Pavlick , Begona Bermejo , Susan G. Hilsenbeck , Mafalda Oliveira , Rachel Schiff , C. Kent Osborne , Mothaffar F. Rimawi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Citation

J Clin Oncol 36, 2018 (suppl; abstr 509)

DOI

10.1200/JCO.2018.36.15_suppl.509

Abstract #

509

Poster Bd #

1

Abstract Disclosures

Similar Posters

First Author: Maria Vidal

First Author: Christian F. Singer

First Author: Emanuela Risi

First Author: Carmine De Angelis